



Express Mail No.: EL844539396 US  
Date of Deposit: August 9, 2002

Attorney's Docket No: L00461/70104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Luiten et al.  
Serial No.: 09/766,889  
Filed: January 19, 2001  
For: MAGE ANTIGENIC PEPTIDES WHICH BIND HLA-B35 and HLA-B44  
Examiner: L. Spector  
Art Unit: 1647  
Conf. No.: 9782

Box Non-Fee Amendment  
Commissioner for Patents  
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the application as follows. Applicants have attached a sheet with the amended paragraph of the specification marked to show insertions (by underlining) and deletions (by bracketing).

In the Specification

Please substitute the Sequence Listing enclosed herewith for the Sequence Listing filed in the application.

Please substitute the following paragraph for the paragraph at page 61, line 27 to page 62, line 11 of the specification:

b2  
Peptide MEVDPIGHLYIFATCL (MAGE-A3<sub>167-182</sub>; SEQ ID NO:57) scored positive. The consensus anchor residues for HLA-B35 are P in position 2 and Y, F, M, L or I in position 9 (Rammensee, H.G., J. Bachmann, and S. Stevanovic. 1997. *MHC Ligands and Peptide Motifs*. Springer, New York). Peptide DPIGHLYIF (SEQ ID NO:58) contained the consensus anchor